|
| |
KDS-4103 Pages on BioPortfolio:
BioPortfolio - faah
Pharmacological profile of the selective FAAH inhibitor KDS-4103 .... In vivo, KDS-4103 inhibits rat brain FAAH activity after intraperitoneal (i.p.) . ...
http://www.bioportfolio.com/search/faah.html...
|
BioPortfolio - Kadmus
KDS- 4103, which was originally. licensed to Kadmus from the University of . ... kadmus kds-4103 - BioPortfolio. ... kadmus kds-4103 Pages on BioPortfolio: ...
http://www.bioportfolio.com/search/Kadmus.html...
|
BioPortfolio - kadmus pharmaceutical
KDS- 4103, which was originally. licensed to Kadmus from the University of . ... Kadmus Pharmaceuticals Inc. The acquisition includes KDS-4103 (URB-597), . ...
http://www.bioportfolio.com/search/kadmus_pharmaceutical.htm...
|
BioPortfolio - kadmus pharmaceuticals inc
Kadmus Pharmaceuticals, Inc. Receives $15.3 Million In Series A Financing ... technology from Kadmus Pharmaceuticals Inc. The. acquisition includes KDS-4103
...
http://www.bioportfolio.com/search/kadmus_pharmaceuticals_in...
|
BioPortfolio - Kadmus Pharmaceuticals URB597 2008
Recent Publications by Kadmus Pharmaceuticals:. • Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). In the present article, . ...
http://www.bioportfolio.com/search/Kadmus_Pharmaceuticals__U...
|
BioPortfolio - kadmus pharma
Kadmus Pharmaceuticals - Entry on Bioportfolio's Biocorporate Database. ... KDS- 4103, which was originally. licensed to Kadmus from the University of . ...
http://www.bioportfolio.com/search/kadmus_pharma.html...
|
BioPortfolio - 3. Kadmus Pharmaceuticals
Denosumab has been evaluated in phase III clinical trials in patients with ... from Kadmus Pharmaceuticals Inc. The acquisition includes KDS-4103 (URB-597),
...
http://www.bioportfolio.com/search/3._Kadmus_Pharmaceuticals...
|
BioPortfolio - Kadmus Pharmaceuticals
such as URB-597 (11, KDS-4103; Kadmus Pharmaceuticals. Inc; Figure 7) which was invented and patented jointly by. the Universities of California, . ...
http://www.bioportfolio.com/search/Kadmus_Pharmaceuticals.ht...
|
BioPortfolio - KAI Pharmaceuticals, Inc.
Johnson - Juvantia - Kadmus - KAI Pharmaceuticals - Kaleidos - Kalypsys . ... technology from Kadmus Pharmaceuticals Inc. The. acquisition includes KDS-4103
...
http://www.bioportfolio.com/search/KAI_Pharmaceuticals,_Inc....
|
BioPortfolio - Kadmus Pharmaceuticals
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). In the present article, we review the pharmacological properties of. ...
http://www.bioportfolio.com/biocorporate/25159-Kadmus_Pharma...
|
Results from other life science and pharmaceutical sites:
Pharmacological profile of the selective FAAH inhi...[CNS Drug Rev ...
In vitro, KDS-4103 inhibits FAAH activity with median inhibitory ... In vivo, KDS-4103 inhibits rat brain FAAH activity after intraperitoneal (i.p.) ...
http://www.ncbi.nlm.nih.gov/pubmed/16834756...
|
Non-linear enzymatic logic in natural product modular mega ...
acquisition includes KDS-4103 (URB-597), a lead FAAH ... based on the development of KDS-4103 and any other. follow-on compounds. KDS-4103, which was
...
http://www.biomedcentral.com/content/pdf/cd-827283.pdf...
|
The fatty acid amide hydrolase inhibitor URB597 (c...[J Pharmacol ...
In the present study, we investigated the effects of the selective FAAH inhibitor URB597 (KDS-4103, cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl
ester) ...
http://www.ncbi.nlm.nih.gov/pubmed/17412883...
|
The endocannabinoid system: A drug discovery perspective Daniele ...
such as URB-597 (11, KDS-4103; Kadmus Pharmaceuticals ... KDS-4103 increases anandamide. levels in the brain, but does not mimic the spectrum of ...
http://www.biomedcentral.com/content/pdf/cd-608185.pdf...
|
Antidepressant-like activity of the fatty acid ami...[Biol ...
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). [CNS Drug Rev. 2006]; The endogenous cannabinoid anandamide has effects on ...
http://www.ncbi.nlm.nih.gov/pubmed/17511970...
|
Enhancement of endocannabinoid signaling and the pharmacotherapy ...
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006;12(1):21–38. [PubMed]. 40. Boger DL, Miyauchi H, Du W, ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21...
|
The fatty-acid amide hydrolase inhibitor URB597 do...[Pharmacol ...
The O-arylcarbamate URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester; also referred to as KDS-4103) is a potent inhibitor of fatty-acid amide
...
http://www.ncbi.nlm.nih.gov/pubmed/16935521...
|
CrossRef Forward Linking Search Results : nature.com
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597). Daniele Piomelli et al. 12 (1), 2006, p. 21. doi:10.1111/j.1527-3458.2006.00021.
x ...
http://www.nature.com/cited/cited.html?doi=10.1038/nn1521...
|
Synergistic antinociception by the cannabinoid receptor agonist ...
... Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS
Drug Rev. ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=19...
|
BioPortfolio - Kadmus Pharmaceuticals
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). In the present article, we review the pharmacological properties of. ...
http://www.bioportfolio.com/biocorporate/5988-Kadmus_Pharmac...
|
|
